MARIPOSA: Amivantamab and Lazertinib in Frontline EGFR-Mutant NSCLC

EP: 1.First-Line Treatment Strategies for Advanced Non–Small Cell Lung Cancer

EP: 2.The Role of CTLA-4 Inhibitors in NSCLC

EP: 3.NSCLC: PD-L1 Expression and Treatment Decision-Making

EP: 4.TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC

EP: 5.Expert Perspectives on the Results of the TROPION-Lung01 Study in NSCLC

EP: 6.EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in Advanced NSCLC

EP: 7.TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC

EP: 8.A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC

EP: 9.First-Line Treatment for EGFR-Mutant Advanced Lung Cancer

EP: 10.FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

Now Viewing

EP: 11.MARIPOSA: Amivantamab and Lazertinib in Frontline EGFR-Mutant NSCLC

EP: 12.Treatment Options in EGFR-Mutant NSCLC in Second Line and Beyond

EP: 13.MARIPOSA-2: Amivantamab and Chemotherapy in EGFR-Mutant NSCLC in Second Line and Beyond

EP: 14.Antibody-Drug Conjugates in EGFR-Mutant NSCLC

EP: 15.Clinical Pearls and Future Perspectives in Advanced NSCLC

This is a synopsis of a Peer Exchange video series featuring Benjamin P. Levy, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Solange Peters, MD, PhD, of University Hospital of Lausanne; Joshua K. Sabari, MD, of NYU Langone’s Perlmutter Cancer Center; Edward B. Garon, MD, MS, of UCLA Jonsson Comprehensive Cancer Center; and Marina Chiara Garassino, MD, of University of Chicago Medicine Comprehensive Cancer Center.

The experts discuss initial results from the phase 3 MARIPOSA-2 trial testing amivantamab plus lazertinib versus osimertinib for untreated EGFR-mutant NSCLC. Dr Sabari explains this three-arm study showed a progression-free survival benefit for the amivantamab-lazertinib combination over osimertinib alone, along with a trend toward improved overall survival. However, he notes additional toxicities like infusion reactions, coagulopathy, and skin rash that require management.

Dr Levy states that while the efficacy results look impressive, determining if the added treatment intensity and toxicity are worthwhile requires considering the patient’s full journey. Dr Garon points out the lack of crossover at progression biases overall survival comparisons to the concurrent chemo-osimertinib arm in the FLAURA2 trial. Dr Peters agrees it is not ideal to directly compare survival outcomes between disparate trials.

The experts concur this exponentially expanding array of first-line options will require careful interpretation and cross-trial comparisons to optimize patient selection. Dr Levy remarks this is an exciting time for the field, but also increasingly complex for practitioners to synthesize all the rapidly emerging data. He states they will need to thoughtfully weigh risks and benefits of more intensive upfront combinations versus sequential treatment strategies for individual patients.

*Video synopsis is AI-generated and reviewed by OncLive editorial staff.